ASTHMA

Welcome to today's episode of Audioboards, in this episode we break down the 2026 GINA Guidelines. 

Transcript

Welcome back to AudioBoards, your high-yield clinical review for the Internal Medicine boards and wards. Today we are executing a deep-dive breakdown of a disease process you see every single week: Asthma. But if you are still managing asthma using old paradigms, your practice is significantly out of date. The Global Initiative for Asthma—or GINA—has completely re-engineered its guidelines.

That's exactly right. The 2026 GINA Strategy Report represents the final, absolute death of short-acting beta-agonist monotherapy. Let’s start with a foundational, language-level paradigm shift. For years, we used the term "mild asthma" to describe patients with infrequent symptoms. GINA 2026 explicitly commands clinicians to avoid the term "mild asthma" in routine practice. What drove this radical shift?

Safety, plain and simple. The data reveals that 30 to 40 percent of patients who suffer a fatal or near-fatal asthma exacerbation were classified as having "mild" asthma prior to the event. Asthma is an underlying, chronic inflammatory disease of the airways. Describing it as "mild" based purely on symptom frequency gives both the patient and the physician a false sense of security, leading to dangerous under-treatment. Inflammation can spike violently at any time when exposed to a potent trigger, like a viral infection or allergen.

So, we treat the inflammation, not just the bronchospasm. But before we write a single script, we have to formally confirm the diagnosis. You should not diagnose asthma based on history alone without objective data. So how do we confirm it?

You must demonstrate variable expiratory airflow limitation. On formal spirometry, look for a classic positive bronchodilator reversibility test. This is strictly defined as an increase in FEV1 of 12% or greater AND an absolute volume increase of 200 mL or greater from baseline, measured 10 to 15 minutes after giving 200–400 mcg of albuterol.

What if the patient is in a clinic or community setting where full spirometry isn't immediately accessible?

GINA notes you can use a Peak Expiratory Flow (PEF) meter. You look for a variable daily PEF variability of greater than 10% in adults. Alternatively, a significant increase in lung function after 4 weeks of anti-inflammatory treatment can also establish the diagnosis.

Let’s get into the meat of long-term outpatient management. GINA has structurally divided treatment for adults and adolescents into two parallel tracks: Track 1 and Track 2. 

Let’s make this crystal clear: Track 1 is the preferred pathway. Why is Track 1 heavily favored by the guidelines?

Because it utilizes an Anti-inflammatory Reliever (AIR). The reliever is a single combination inhaler containing a low dose of an Inhaled Corticosteroid (ICS) combined with formoterol.

Let's pause on the pharmacology there. Formoterol is a Long-Acting Beta-Agonist (LABA), which historically we were told never to use as a rescue because LABAs are typically slow-acting. Why is formoterol the exception?

Formoterol has a unique chemical structure that allows it to achieve rapid-onset bronchodilation—within 1 to 3 minutes—exactly like albuterol, while lasting up to 12 hours. By pairing low-dose ICS with formoterol in a single device, every single time the patient feels a tight chest and reaches for their rescue inhaler, they are automatically delivering a micro-dose of anti-inflammatory budesonide or mometasone directly to the inflamed airway tissue. It completely bypasses the human behavior problem of poor daily controller adherence.

Let’s break down the actual steps of Track 1 (The Preferred AIR/MART Pathway). How do we progress a patient through the stages? 

The criteria for assigning a starting asthma step are based entirely on symptom frequency: Steps 1 & 2 are for symptoms occurring less than 4 to 5 days a week, Step 3 is for symptoms occurring most days or waking up at night once a week or more, Step 4 is for daily symptoms with low lung function or a recent severe flare-up, and Step 5 is for asthma that remains completely uncontrolled despite high-dose Step 4 treatment.

Steps 1 & 2: For patients with infrequent symptoms (less than 4–5 days a week), the treatment is purely as-needed low-dose ICS-formoterol. There is no daily scheduled inhaler. They use it only when they have symptoms.

Step 3: If they have symptoms most days or wake up at night once a week or more, they transition to MART(Maintenance and Reliever Therapy). They now take 1 inhalation of low-dose ICS-formoterol daily as their scheduled maintenance, and use that exact same inhaler as-needed for rescue.

Step 4: If they remain uncontrolled, you scale up to medium-dose ICS-formoterol as their scheduled daily maintenance, continuing to use the same device as-needed for relief.

Step 5: This is severe asthma. You optimize them on high-dose ICS-LABA, consider adding a Long-Acting Muscarinic Antagonist (LAMA) like tiotropium to create triple therapy, and refer to them for phenotypic biologic assessment.

That is incredible. One device handles everything from Steps 1 through 4. Now, let’s talk about Track 2 (The Alternative Pathway). When do we use it, and how does it differ?

Track 2 is your fallback option. You use it if Track 1 is completely unavailable, unaffordable, or if a patient has been perfectly controlled on a traditional regimen for years and is explicitly resistant to changing devices. In Track 2, the rescue inhaler is your traditional Short-Acting Beta-Agonist (SABA), like albuterol.

But what is the ironclad rule regarding SABAs in Track 2?

SABA monotherapy is completely obsolete and clinically dangerous. If a patient is in Track 2, they must take an anti-inflammatory controller.

In Step 1, whenever they take a puff of their SABA rescue, they must immediately take a separate puff of a low-dose ICS.

In Step 2, they must take a daily, scheduled low-dose ICS controller, plus their SABA as-needed.

In Steps 3 & 4, they transition to daily scheduled ICS-LABA maintenance (like fluticasone-salmeterol) with a separate SABA rescue.

If they are overusing their SABA—meaning they are burning through 3 or more canisters per year—their risk of an ER visit or death spikes dramatically, and you must step them up.

Let’s pivot to Step 5: Difficult-to-treat and Severe Asthma. If a patient is taking high-dose ICS-LABA, using their inhaler with perfect technique, and you've ruled out modifiable risk factors like smoking or GERD, but they are still flaring up, what is the next step?

You must perform advanced phenotyping to look for Type 2 (T2) High Airway Inflammation. T2 inflammation is driven by eosinophils, mast cells, and specific interleukins. We identify this phenotype using three easily accessible clinical biomarkers:

Blood Eosinophils: A count of ≥ 150 to 300 cells/μL.

FeNO (Fractional Ex exhaled Nitric Oxide): A level of ≥ 20 parts per billion (ppb).

Sputum Eosinophils: ≥ 2% (though less commonly done in non-academic centers).

If the patient satisfies these T2-high criteria, we can target their specific inflammatory cascade with biologic therapies. Let’s do a rapid-fire board review of the monoclonal antibodies available in 2026.

Let's break them down by their molecular targets:

Anti-IgE (Omalizumab): Best for patients with severe, proven perennial allergic asthma with elevated total serum IgE levels.

Anti-IL5 / Anti-IL5R (Mepolizumab, Reslizumab, Benralizumab): These target eosinophil survival. Outstanding for patients with severe eosinophilic asthma and recurrent exacerbations.

Anti-IL4Ra (Dupilumab): Blocks both IL-4 and IL-13 signaling. Excellent for severe eosinophilic asthma, especially if the patient has comorbid severe atopic dermatitis or chronic rhinosinusitis with nasal polyps.

Anti-TSLP (Tezepelumab): An anti-alarmin biologic that acts high up in the epithelial cascade. Because it acts at the very top of the inflammatory stream, it is effective for both T2-high and some T2-low severe asthma phenotypes.

Let’s move from the outpatient clinic straight to the Emergency Department and the medical wards. A patient presents with an acute asthma exacerbation. They are tachypneic, wheezing, and using accessory muscles. Walk us through the immediate evaluation and triage.

You need to rapidly differentiate between a mild-to-moderate flare and a severe, life-threatening exacerbation.

Severe signs: The patient cannot speak in full sentences, prefers sitting hunched forward, has a respiratory rate greater than 30 breaths per minute, a heart rate greater than 120 beats per minute, or an O2 saturation less than 90% on room air.

Life-threatening signs ("Silent Chest"): Confusion, lethargy, a paradoxical chest-abdominal wall movement, or a normal-to-elevated PaCO2 on an arterial blood gas. Remember: an asthmatic who is hyperventilating should have a low PaCO2 . A normal or rising PaCO2 means their respiratory muscles are fatiguing—this is an absolute peri-intubation emergency.

Once we've triaged them, what is our immediate, first-line medical management cocktail in the acute setting?

You initiate three interventions simultaneously:

Oxygen Therapy: Titrate to a target saturation of 93% to 95% in adults (or 94–98% in pregnant patients). Do not over-oxygenate.

Repetitive or Continuous Inhaled SABA: Administer 4 to 10 puffs of albuterol via an MDI with a spacer every 20 minutes for the first hour, or use continuous nebulization. Combine this with Inhaled Ipratropium Bromide (SAMA) for severe exacerbations; adding ipratropium reduces hospitalization rates.

Systemic Corticosteroids: Do not wait. Give oral prednisone (40–50 mg daily) or intravenous methylprednisolone if the patient is vomiting or in severe respiratory distress. A typical course is 5 to 7 days, and you do not need to taper it if it's a short course.

What about medications that people frequently try to use but are explicitly not routinely recommended by GINA for acute flares?

Avoid routine intravenous magnesium sulfate unless the patient has severe distress and has failed to respond to the initial hour of intensive bronchodilators. Definitely avoid routine antibiotics unless there is clear, objective evidence of a secondary bacterial infection like pneumonia. And absolutely avoid routine sedatives or anxiolytic medications, which can suppress respiratory drive.

Once the patient stabilizes on the floor and is ready for discharge, what must we verify before they walk out the hospital doors?

You cannot just hand them a script and leave. Before discharge, you must:

Review and physically witness their inhaler technique.

Provide a written Asthma Action Plan so they know exactly how to scale up their doses if their PEF drops.

Discharge them with an ICS-containing regimen (preferably Track 1) to prevent a rebound flare.

Arrange a formal outpatient follow-up appointment within 1 to 2 weeks.

To wrap things up, let's look at the long-term maintenance phase. The patient is doing beautifully, their asthma is completely controlled, and they want to know if they can stop or decrease their medications. What are the rules for stepping down?

Never step down during an active upper respiratory infection or while they are traveling. GINA recommends considering a step-down only after the patient’s symptoms have been fully controlled and their lung function has been completely stable for at least 3 months.

When you do step down, reduce the ICS component gradually by 25% to 50%. If they are on Track 1 MART, you can simply reduce their daily scheduled maintenance dose while keeping their as-needed rescue unchanged. Always document their baseline function prior to the change, ensure they have enough medication to immediately resume their previous dose if they flare, and see them back in the clinic in 4 to 6 weeks to re-evaluate.

Incredible. Let’s bring it all home with our ultra-high-yield recap:

Drop "Mild Asthma": Airway inflammation is chronic; severe attacks can happen regardless of baseline symptom frequency.

Diagnosis: Look for an FEV1 increase of 12% or greater and 200 mL or greater post-bronchodilator.

Track 1 (Preferred): Employs low-dose ICS-formoterol as an As-Needed Anti-inflammatory Reliever (AIR) or as Maintenance and Reliever Therapy (MART).

Track 2 (Alternative): Uses SABA for relief, but it must be paired with an ICS puff. SABA monotherapy is completely dead.

Severe Asthma Phenotyping: Check blood eosinophils (≥150–300) and FeNO (≥20 ppb) to identify Type 2 inflammation for targeted biologic therapies (anti-IgE, anti-IL5, anti-IL4Ra, anti-TSLP).

Acute Flare Cocktail: High-dose SABA + SAMA, early systemic corticosteroids, and titrated oxygen (93–95%). Watch out for a normal or rising PaCO2 .

Step-Down Window: Ensure 3 full months of complete stability before attempting a 25–50% reduction in ICS dose.

That’s a wrap for this episode. 

Thanks for listening to AudioBoards. Stay tuned for more educational content in our next episode! The views and opinions expressed on the AudioBoards Podcast do not necessarily reflect those of our employers. This podcast is for educational purposes only and should not be used to diagnose or treat any medical conditions. It is not a substitute for professional medical advice. Always consult a qualified, board-certified healthcare provider for any medical concern.